主页 > 医学讨论 >
【商业翻译】（医师报约稿）Rotigotine As Levodopa
2.本星期三（5.16）晚上十点前交稿
3.格式见置顶的文摘编译格式：http://www.dxy.cn/bbs/post/view?bid=116&id=8600034&sty=1&tpg=1&age=0
4.稿酬按医师报标准
5.为保证翻译质量起见，在本版得分超过15分以上的战友方可认领
6.每位战友最多认领2篇,编译群战友可根据自己的专业和精力，最多认领3篇
7.作者统一署名为"丁香"
8.质量第一，切切
Rotigotine As Levodopa Adjunct Is Effective In Advanced Parkinson's Disease
Transdermal rotigotine (Neupro) up to doses of 8 and 12 mg/day as adjunctive therapy to levodopa significantly decreases "off time" in patients with advanced Parkinson's disease, according to phase III data presented at the 59th Annual Meeting of the American Academy of Neurology (AAN).
Peter A. LeWitt, MD, professor of neurology at Wayne State University in Milwaukee, Wisconsin, reported results in 351 patients with advanced idiopathic Parkinson's disease who had been randomized to placebo or two target doses of rotigotine (up to either 8 mg/24h or 12mg/24h) for up to seven months. Rotigotine is a non-ergolinic dopamine receptor agonist available as a patch for once-daily use.
The trial, known as Prospective Randomized Evaluation of a new Formulation: Efficacy of Rotigotine (PREFER), included a five-week titration phase followed by a 24-week maintenance phase.
The primary efficacy variable was change from baseline in absolute off time.
Compared to baseline, mean daily decreases in off time were 2.7 hours with the 8mg/24h dose and 2.1 hours with the 12mg/24h dose compared to a 0.9 hour decrease with placebo (P<0.001 and 0.003, respectively).
Patients who had longer off times at enrollment tended to benefit most. The study also found that "on" time without dysykinesia after awakening was more than doubled in the two rotigotine groups compared with placebo.
The most common adverse events in the rotigotine groups were application site reactions, somnolence, nausea and vomiting, and dizziness.
While many patients with advanced Parkinson's disease have a surge in symptoms between dosages of their medications, the 24-hour duration of transdermal rotigotine offers the potential for extended anti-parkinsonian control lasting through the night into the morning hours after awakening, Dr. LeWitt said.
Rotigotine is a non-ergolinic dopamine receptor agonist formulated as a path for once-daily usage. The study was sponsored by Schwarz Pharma. Rotigotine As Levodopa Adjunct Is Effective In Advanced Parkinson's Disease
左旋多巴辅助药物罗替戈汀（Rotigotine）对晚期帕金森(氏)病治疗有效。
Transdermal rotigotine (Neupro) up to doses of 8 and 12 mg/day as adjunctive therapy to levodopa significantly decreases "off time" in patients with advanced Parkinson's disease, according to phase III data presented at the 59th Annual Meeting of the American Academy of Neurology (AAN).
发表在美国神经病学学会(AAN)第59界年会的III期资料表明，作为左旋多巴的辅助治药物，罗替戈汀透皮帖剂(罗替戈汀透皮传递系统)每天的剂量逐渐增加至8 mg或12mg/天时，能显著减少晚期帕金森(氏)病患者的"药效间隙期"。
Peter A. LeWitt, MD, professor of neurology at Wayne State University in Milwaukee, Wisconsin, reported results in 351 patients with advanced idiopathic Parkinson's disease who had been randomized to placebo or two target doses of rotigotine (up to either 8 mg/24h or 12mg/24h) for up to seven months. Rotigotine is a non-ergolinic dopamine receptor agonist available as a patch for once-daily use.
韦恩州立大学神经病学教授、医学博士Peter A. LeWitt 报告了一些研究结果，351名晚期原发性帕金森(氏)病患者被随机分配接受7个月的安慰剂或双目标剂量（逐渐增加剂量至8 mg或12mg/24h）治疗。罗替戈汀是现有非二氢麦角碱多巴胺受体激动剂中可作为每日一次使用的辅助药物。
The trial, known as Prospective Randomized Evaluation of a new Formulation: Efficacy of Rotigotine (PREFER), included a five-week titration phase followed by a 24-week maintenance phase.
称为新配方的前瞻性随机评价，既罗替戈汀药效(PREFER)的试验，包括一个5周的滴定期和随后24周的维持期。
The primary efficacy variable was change from baseline in absolute off time.
主要药效变量是指自绝对"药效间隙期"基线的变幅。
Compared to baseline, mean daily decreases in off time were 2.7 hours with the 8mg/24h dose and 2.1 hours with the 12mg/24h dose compared to a 0.9 hour decrease with placebo (P<0.001 and 0.003, respectively).
相对于基线，8mg/24h剂量组患者药效间歇期平均每天减少2.7小时，12mg/24h剂量组每天减少2.1小时，而安慰剂组减少0.9小时(P<0.001 和 0.003)。
Patients who had longer off times at enrollment tended to benefit most. The study also found that "on" time without dyskinesia after awakening was more than doubled in the two rotigotine groups compared with placebo.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-12 05:11
医学,生命科学网